Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Amgen Inc. (AMGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for AMGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
|% Held by Insiders||0.19%|
|% Held by Institutions||78.03%|
|EPS (last reported FY)||$12.58|
|EPS (last reported Q)||$2.89|
|EPS, estimated (last reported Q)||$3.04|
|Total revenues||$23 B|
|Net income||$2 B|